solution peptides glp-3 retatrutide GLP-3 RT – True Lab

The GLP-1 compounding market changed significantly in 2025-2026 under FDA enforcement

The global TRIUMPH Phase 3 program is now assessing retatrutide in obesity , type 2 diabetes , obstructive sleep apnea , knee osteoarthritis , and cardiovascular outcomes

Results In all, 39 pwIIH (mean age 33.6 years [SD 8.0], 92.3% female, median BMI 36.3 kg/m 2 [IQR 31.438.3]) were included, with 13 pwIIH being treated with GLP-1-RAs and remaining adherent to the treatment throughout the study

This makes peptides generally easier to synthesize and often more targeted in their receptor interactions

This cardiovascular protection earned Ozempic a dedicated indication for reducing cardiovascular risk

Preclinical studies demonstrate their capacity to reduce retinal ganglion cell apoptosis in diabetic models (Wang et al., 2023)